Skip to search boxSkip to navigationSkip to main content

Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress

*Corresponding author for this work
  • Universidade de São Paulo
    ,
  • Medical College of Georgia
    ,
  • University of Ottawa
    ,
  • University of Glasgow
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Vascular inflammatory responses play an important role in several cardiovascular diseases. Of the many pro-inflammatory vasoactive factors implicated in this process, is aldosterone, an important mediator of vascular oxidative stress. Statins, such as atorvastatin, are cholesterol-lowering drugs that have pleiotropic actions, including anti-oxidant properties independently of their cholesterol-lowering effect. This study investigated whether atorvastatin prevents aldosterone-induced VSMC inflammation by reducing reactive oxygen species (ROS) production. Vascular smooth muscle cells (VSMC) from WKY rats were treated with 1 μM atorvastatin for 60 min or for 72 h prior to aldosterone (10 -7 mol/L) stimulation. Atorvastatin inhibited Rac1/2 and p47phox translocation from the cytosol to the membrane, as well as reduced aldosterone-induced ROS production. Atorvastatin also attenuated aldosterone-induced vascular inflammation and macrophage adhesion to VSMC. Similarly EHT1864, a Rac1/2 inhibitor, and tiron, ROS scavenger, reduced macrophage adhesion. Through its inhibitory effects on Rac1/2 activation and ROS production, atorvastatin reduces vascular ROS generation and inhibits VSMC inflammation. Our data suggest that in conditions associated with aldosterone-induced vascular damage, statins may have vasoprotective effects by inhibiting oxidative stress and inflammation.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 29-34 (6 pages)

Journal (Volume, Issue Number)

Life sciences (Volume 221)

Publication milestones

  • Published - 03/15/2019

Publication status

Published - 03/15/2019

ISSN

0024-3205

Publication IDs

  • Scopus: 85061227528
  • PubMed: 30721707

Publication metrics

Metrics

SciVal
citations
8
SciVal
FWCI
2.11
SciVal
Author count
6
SciVal
Paper percentile
85
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
37
Captures
38

Funding Details

This work was supported by the São Paulo Research Foundation [grant numbers 2010/52214-6 (to R.C.T); 2011/01785-6 ; 2011/22035-5 (to T.B.-N.)]; Coordination for the Improvement of Higher Education Personnel (CAPES) [grant number: 88887.092495/2015-00 (to T.B.-N)]; the Agence Universitaire de la Francophonie [grant number 58145FT103 ]; the Juvenile Diabetes Research Foundation [grant number 4-2010-528 ]; the Canadian Institutes of Health Research [grant number 44018 ]; and the British Heart Foundation [grant number CH/12/429762 ].
FundersFunding numbers
BHF
CH/12/429762
CIHR
44018
FAPESP
2011/22035-5, 2011/01785-6, 2010/52214-6
NHLBI
R01HL130301
AUF
58145FT103
JDRF
4-2010-528
CAPES
88887.092495/2015-00